Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04300751 · ClinicalTrials.gov registry record · Phase 1

The Behavioral Effects of Opioids and Alcohol

A Phase 1 study of Opioid Use and Alcohol Drinking, sponsored by Sharon Walsh.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target
1
Study location

NCT04300751: Completed Phase 1 study of Opioid Use and Alcohol Drinking, sponsored by Sharon Walsh.

NCT04300751 is a Phase 1 study of Opioid Use and Alcohol Drinking that has completed, run by Sharon Walsh. The registered enrollment target is 11 participants, below the 148,260-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04300751, a Phase 1 study of Opioid Use and Alcohol Drinking, has completed, sponsored by Sharon Walsh.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

This study will examine the effects of doses of alcohol/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.

Primary Outcome

Participants rated their subjective drug liking on a standardized VAS scale (0 to 100; 0=Not at all, 100=Extremely). A higher score indicates greater drug liking. This outcome was recorded multiple times at regular intervals throughout the experimental dose condition sessions. For each dose condition, the participants' peak value was pulled from the raw data and averaged to yield one mean (SEM).

Interventions

  • DRUG Alcohol
  • DRUG Opioid Agonist

Study Locations (1)

Kentucky

  • University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2021-03-24
Est. Completion 2024-11-09
Phase Phase 1
Sharon Walsh

4 total trials

What the finished NCT04300751 record still lists

NCT04300751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 148,260-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Opioid Use appearing as the primary indexed condition, and to 2 interventions - of which Alcohol is the first listed.

NCT04300751 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT04300751 about?

NCT04300751 is a clinical study titled "The Behavioral Effects of Opioids and Alcohol". This study will examine the effects of doses of alcohol/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction...

What is the current status of trial NCT04300751?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2021-03-24. Estimated completion is 2024-11-09.

What conditions does trial NCT04300751 study?

This clinical trial studies the following conditions: Opioid Use, Alcohol Drinking.

What interventions are being tested in trial NCT04300751?

The interventions under investigation include: Alcohol (DRUG), Opioid Agonist (DRUG).

Who is sponsoring clinical trial NCT04300751?

This trial is sponsored by Sharon Walsh, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04300751 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04300751's enrollment target sits among peer trials

11 106th of 105 the lowest of 105 other Opioid Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04300751, the US trial registry maintained by the National Library of Medicine. NCT04300751 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.